Recursion reports strong Q1 progress with promising cancer drug trials and extends cash runway to early 2028

Recursion Pharmaceuticals announced positive first-quarter 2026 results, highlighting early clinical success in cancer drug candidates REC-1245 and REC-4539, and strong Phase 2 signals for REC-4881. The company’s AI-driven drug discovery platform accelerated development timelines and demonstrated favorable safety and pharmacokinetics in trials. Financially, Recursion reduced its net loss to $117.5 million and maintained a cash position supporting operations into early 2028 without additional funding. Upcoming milestones include further clinical data and regulatory updates expected through 2026 and 2027.